Tirzepatide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Tirzepatide is fully FDA-approved for human use under two brand names: Mounjaro (NDA 215866, approved May 2022) for type 2 diabetes mellitus as an adjunct to diet and exercise, and Zepbound (NDA 217806, approved November 2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidity, with a supplemental indication approved in 2024 for obstructive sleep apnea in adults with obesity. It is a prescription-only drug and is not a controlled substance under the Controlled Substances Act. As a fully approved drug, tirzepatide is not subject to the FDA Category 1/2 bulk-peptide compounding restrictions under docket FDA-2025-N-6895 that govern unapproved research peptides. The FDA declared the tirzepatide drug shortage resolved in October 2024, ending the shortage-based exemption for 503B outsourcing-facility compounding; 503B compounding authority for tirzepatide ended March 19, 2025. On April 30, 2026, FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B Bulk Drug Substances List, citing no clinical need given adequate commercial supply (Federal Register; public comment deadline June 29, 2026). 503A patient-specific pharmacy compounding of tirzepatide is subject to the standard prohibition on essentially copying commercially available drugs, except in limited documented circumstances (e.g., documented allergy to inactive ingredients). Branded Mounjaro and Zepbound remain commercially available by prescription.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Tirzepatide

Origin

Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. Its sequence is derived from the native glucose-dependent insulinotropic polypeptide (GIP) scaffold, with selective modifications that confer simultaneous agonist activity at both the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). A C20 fatty-diacid chain is attached via an aminoisobutyric acid (Aib) and mini-PEG spacer at lysine-26, enabling reversible albumin binding that extends the plasma half-life to approximately 120 hours and supports once-weekly subcutaneous administration. Tirzepatide received FDA approval in May 2022 as Mounjaro (NDA 215866) for type 2 diabetes mellitus and in November 2023 as Zepbound (NDA 217806) for chronic weight management and, in 2024–2025, for obstructive sleep apnea (OSA) in adults with obesity.

Registry IDs

PubChem CID

166567236

CAS

2023788-19-2

InChIKey

BTSOGEDATSQOAF-MCNPHUAVSA-N

Molecular formula

C225H348N48O68

Molar mass

4813 g/mol

Monoisotopic

4810.5248574 Da

InChIKey

BTSOGEDATSQOAF-MCNPHUAVSA-N

Appearance

Clear, colorless to slightly yellow solution in prefilled single-dose pen injector (commercial presentations). Molecular weight approximately 4813 Da (C225H348N48O68).

Solubility

Soluble in aqueous buffers at physiological pH. The C20 fatty-diacid chain with …

Sequence not available in current seed.

Stability: The fatty-acid/mini-PEG conjugation enables albumin binding that substantially shields the peptide backbone from proteolytic degradation and renal clearance, ac

Vial sizes

null mg · null mg

Purity grades

pharmaceutical grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Tirzepatide acts as an imbalanced dual agonist with receptor-binding affinity for the GIPR matching that of native GIP, while affinity for the GLP-1R is approximately fivefold lower than native GLP-1 — a deliberate design that engages complementary incretin pathways
• At the GLP-1R, tirzepatide exhibits biased agonism, preferentially driving cyclic AMP (cAMP) generation over beta-arrestin recruitment; because beta-arrestin 1 normally limits the insulin secretory response to GLP-1R activation, this bias amplifies glucose-dependent insulin secretion beyond what a balanced GLP-1R agonist achieves
• Activation of both receptors in pancreatic beta cells potentiates glucose-dependent insulin secretion and suppresses glucagon from alpha cells, reducing postprandial glycemic excursions while minimizing hypoglycemia risk
• Central GLP-1R and GIPR signaling in the hypothalamus and brainstem reduces appetite, prolongs satiety, and modulates reward-related feeding behavior, producing dose-dependent reductions in caloric intake and body weight that exceed those seen with selective GLP-1R agonists in head-to-head trials

Pharmacokinetics (ADME)

Half-life

Approximately 120 hours (~5 days) after subcutaneous injection; supports once-weekly dosing. Steady-state plasma concentrations achieved after approximately 4 weeks.

Clearance

Apparent mean population clearance approximately 0.061 L/h per population PK analysis. Absolute subcutaneous bioavailability approximately 80%. Tmax 8–72 hours post-injection.

PK–PD note: Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty-acid chain; excretion is primarily renal and fecal as metabolites. High plasma-protein bindin…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Liu, Shi, Xie, Sun & Nahata 2025, Pharmaceuticals 18(5):668 — systematic review & meta-analysis of RCTs — 603 records identified, 418 screened, 14 RCTs / 14,713 patients — the formal PRISMA anchor for the diabetes/obesity RCT base. Jan-2024 search cutoff, so it does NOT include the six later pivotal trials cited below.
• Dong, Xu, Gan, Zhang, He & Tang 2026, Medicinal Research Reviews 46(4):1026-1041 — multisystem review — Cardiovascular / MASH / renal benefit signals flagged as still emerging: 'largely based on case reports, post hoc analyses, and non-prespecified endpoints' outside core T2D/obesity.
• Coskun et al. 2018, Molecular Metabolism 18:3-14 — 'From discovery to clinical proof of concept' — The mechanistic anchor (dual-receptor cAMP pharmacology + DIO-mouse efficacy + first Phase 1b proof-of-concept) and the earliest indexed tirzepatide/LY3298176 record.
• Nicholls et al. 2025, NEJM — SURPASS-CVOT (NCT04255433) — 13,299 T2D+ASCVD patients; tirzepatide NONINFERIOR (not superior) to dulaglutide for 3-point MACE (HR 0.92, p=0.003 noninferiority, p=0.09 superiority). Pivotal CV-outcomes cite post-dating the meta-analysis.
• Packer et al. 2024/25, NEJM — SUMMIT (NCT04847557) — HFpEF + obesity; reduced CV death / worsening HF (36 [9.9%] vs 56 [15.3%], HR 0.62, p=0.026). Online-first Nov 16 2024.
• Malhotra et al. 2024, NEJM — SURMOUNT-OSA (NCT05412004) — The real obstructive-sleep-apnea trial. NB: seed prose mislabels NCT05822830 (SURMOUNT-5) as SURMOUNT-OSA — flagged for seed maintainer, not corrected in this overlay.
• Aronne et al. 2025, NEJM — SURMOUNT-5 (NCT05822830, PMID 40353578) — Head-to-head tirzepatide vs semaglutide in obesity/overweight — a separate trial from SURMOUNT-OSA.

5 registered trials — 0 currently recruiting.

—
NCT06914141
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

COMPLETED

Phase 4
NCT06009653
Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

WITHDRAWN

Phase 1
NCT03951753
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

COMPLETED

Phase 3
NCT05822830
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

COMPLETED

Phase 3
NCT03987919
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

COMPLETED

Summary (literature)

Tirzepatide's adverse-effect profile is consistent with the incretin drug class. Gastrointestinal events are the most common: nausea (approximately 30–40%), diarrhea (approximately 20–25%), vomiting (approximately 15–18%), and constipation (approximately 12–15%) — predominantly m…

WADA status

As of the 2026 WADA Prohibited List (effective January 1, 2026), tirzepatide is NOT classified as a prohibited substance in sport. Tirzepatide and semaglutide a…

Dominant research route: Virtually the entire tirzepatide research and clinical-development program — the pivotal SURPASS (type 2 diabetes) and SURMOUNT (obesity) trials, the approved Mounjaro/Zepbound label, the radiolabeled ADME/mass-balance study, and the injection-site comparison study — used SUBCUTANEOUS administration exclusively; SC is also the only clinically approved route. Rodent mechanism/efficacy studies most often mirror this with SC, though some use IP. The only human IV data come from a single Phase 1 reference-dose comparison used solely to calculate absolute bioavailability. A small, unaffiliated, sponsor-funded oral-capsule pilot (n=9) is the only investigational departure from SC and remains preliminary/unreplicated.

The sole route in the entire human clinical-development program and the only FDA-approved route: the SURPASS (T2D) and SURMOUNT (obesity) registration programs, thousands of patients. A dedicated Phase 1 study compared abdomen/thigh/upper-arm injection; a separate single-dose [14C]-radiolabeled mass-balance/ADME study used SC dosing.

Bioavailability: Mean absolute bioavailability ~80% (established against an IV reference dose in a Phase 1 single-dose absolute-BA study, 'Study 7'; also stated on the FDA Mounjaro label). Median Tmax 24 h (8–72 h); steady state after ~4 weeks of once-weekly dosing; elimination half-life ~5 days. In a human [14C] mass-balance study (~2.9 mg SC), ~66% of administered radioactivity was recovered in urine and ~33% in feces — as metabolites (proteolytic backbone cleavage, C20 fatty-diacid beta-oxidation, amide hydrolysis), not intact drug. Comparable exposure across abdomen/thigh/upper-arm sites.

The only route Eli Lilly has developed, studied in registration trials, and received FDA approval for (Mounjaro for T2D, Zepbound for weight management). No human-dosing protocol implied.

Used only as the reference dose in the Phase 1 single-dose human crossover ('Study 7': 5 mg SC vs 5 mg IV) run to calculate absolute bioavailability. Never used in any registration trial or the approved product.

Bioavailability: 100% bioavailable by definition; the IV arm anchors the ~80% absolute SC-bioavailability figure built into the population-PK model submitted with the NDA.

A reference-only research route for a bioavailability calculation, never an administered or approved clinical route. No human-dosing protocol implied.

No oral formulation of tirzepatide itself has been developed or trialed by Eli Lilly. An unaffiliated company, Lexaria Bioscience, ran a small (n=9), sponsor-funded, randomized crossover pilot ('Human Pilot Study #3') of its proprietary lipid-conjugated ('DehydraTECH') oral tirzepatide capsule (20 mg once daily x7 days) vs a single 2.5 mg injected Zepbound dose.

Bioavailability: Company-reported (not peer-reviewed) blood levels described by Lexaria's press release as 'roughly equal end-of-study levels' vs the injected reference, with fewer reported adverse events — a narrow end-of-study trough comparison after 7 daily oral doses vs one injection, which does NOT establish comparable bioavailability/Cmax/AUC. No oral-bioavailability percentage for unmodified tirzepatide has been published by any primary source; any oral signal depends entirely on the third-party absorption-enhancing formulation, not an intrinsic property of the peptide.

Sponsor-funded, small (n=9), single pilot disclosed via company press release + SEC filing — NOT an independent peer-reviewed publication or a registered trial; treat as a preliminary, attributed sponsor claim pending replication. No human-dosing protocol or efficacy implied.

No published pharmacokinetic or clinical study of intranasal tirzepatide was found. Sold as a nasal-spray product by research-chemical vendors, explicitly labeled 'for research use only, not for human consumption.'

Bioavailability: No intranasal pharmacokinetic or bioavailability data exists for tirzepatide in any species.

A vendor-marketed, unstudied route with no independent evidence behind it. No human dosing or efficacy implied.

Used as a systemic dosing route in some rodent preclinical pharmacology, e.g. a streptozotocin/high-fat-diet diabetic-rat study of CNS/cognitive endpoints (1.35 mg/kg once weekly). Animal-only; not a human route.

Bioavailability: No dedicated IP pharmacokinetic characterization was found; IP is a convenient systemic-dosing route in this rodent efficacy study rather than a PK-study route. Other rodent tirzepatide work (e.g. brown-adipose-tissue studies) instead uses subcutaneous dosing to mirror the human route.

A laboratory-animal administration route, cited only to describe how some preclinical work was conducted. No human route or dosing protocol implied.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $3.27 · median $8.90 · p75 $10.40 · 10 researched vendors

Legit, COA-backed band: $3.00–$13.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$15

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Aggregate third-party testing (Finnrick marketplace, 2,188 samples / 176 vendors, 17 Dec 2024 – 16 Jun 2026) reports tirzepatide purity clustering roughly 98.8–99.95% HPLC (5th–95th percentile) among tracked vendors — comparable to the reputable band for other research peptides. No independently-confirmed low-tier (<90%) tirzepatide sample was found this pass (an honest gap in the public record, not evidence the grey market is cleaner). A laboratory-industry guide (Contract Laboratory) cautions that tirzepatide's size/complexity (39 amino acids plus a C20 fatty-diacid side chain) makes it harder to resolve from synthesis-related impurities on generic HPLC than smaller peptides.

Independent labs cited for this compound

No recall of an FDA-approved Mounjaro/Zepbound lot, and no recall of an RUO-labeled 'research peptide' tirzepatide product, was found this pass. Real recalls do exist, but every one traces to the licensed 503A/503B compounding-pharmacy channel: ProRx (Aug 2024, 16,604 semaglutide+tirzepatide vials; Oct 2025, 2,761 tirzepatide-specific vials), GenoGenix (Jul 2025), and New Life Pharma (Feb 2026) — all Class II sterility recalls, not potency/identity recalls. FDA's grey-market/research-vendor enforcement runs through warning letters and import alerts rather than formal recalls, which is why none appear there — not evidence that channel is cleaner.

Buyer red-flag checklist

• No batch-specific COA with BOTH HPLC purity AND LC-MS identity confirmation — for a large, complex 39-amino-acid lipidated dual agonist, purity alone can't rule out substitution.
• Product marketed as 'tirzepatide sodium' or 'tirzepatide acetate' as if interchangeable with the FDA-approved free-base peptide — FDA has flagged salt forms as unapproved for compounding (the explicit bioequivalence finding on FDA's page is for semaglutide; no primary FDA bioequivalence determination for tirzepatide salts was found).
• Listing under a coded or non-standard name ('GLP-2 peptide,' 'GLP1-T,' etc.) to obscure that the product is tirzepatide — the exact pattern cited in the March 2026 FDA warning letters.
• Bacteriostatic water bundled with the peptide vial — FDA treats this as evidence of intended human injection use, undercutting a 'research use only' label.
• No documented sterility/endotoxin testing on a lyophilized product implied for reconstitution and injection — the defect behind the ProRx, GenoGenix, and New Life Pharma recalls.
• Human-dosing, weight-loss-percentage, or blood-sugar marketing claims on a 'research use only' storefront (the pattern in the Prime Sciences warning letter).
• COA reports only a purity percentage with no separate fill-weight/quantity assay — purity is not potency for this peptide; a 99%+ pure vial can still be substantially underfilled.
• Price far below the going market rate for a molecule this synthetically complex — a classic underfill/adulteration signal — or a compounded-with-B12 combination product, given Lilly's March 2026 undisclosed-impurity finding.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Fill-weight/potency divergence, not raw HPLC purity, is the more pronounced tirzepatide-specific risk. The same Finnrick aggregate shows mg-quantity-vs-label divergence reaching roughly +/-43–49% at the 95th percentile (2,188 samples/176 vendors); an earlier, smaller snapshot (194 samples/36 vendors) showed an even wider ~+/-104% tail, consistent with a growing dataset. Vendor-level examples: Peptide Sciences samples labeled 5 mg assayed as low as 3.89 mg (~22% shortfall); Planet Peptide roughly -9% to -14% under label. 0.2 is a directional estimate synthesizing these figures, not a formal prevalence study — provisional pending the live crawler/lab-aggregate pipeline.

• Import Alert 66-80 (launched 19 Sep 2025, 'Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances') authorizes DWPE of GLP-1/GIP bulk drug substances — expressly including tirzepatide — from foreign manufacturers not on FDA's vetted 'Green List' (the Green List itself was announced 5 Sep 2025). The broader Import Alert 66-41 (unapproved new drugs promoted in the US) can also reach tirzepatide sold outside an approved application, but does NOT name tirzepatide specifically. An RUO label is not an import exemption — CBP judges actual intended use.66-80 (GLP-1 receptor-agonist bulk drug substances) + 66-41 (unapproved new drugs, general)
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

NOT on WADA's Prohibited List (including S4). Tirzepatide (with semaglutide) sits on WADA's Monitoring Program only — tirzepatide added for the 2026 program (effective 1 Jan 2026) so anti-doping labs can track patterns of use without imposing sanctions; USADA states plainly that 'GLP-1s are not prohibited in sport' and no Therapeutic Use Exemption is required. [Verification: vendor-blog claims that GLP-1 receptor agonists 'moved to full S4 prohibition effective January 2026' could NOT be confirmed against USADA/WADA guidance (which list tirzepatide as MONITORED, not prohibited) and are treated as an incorrect claim — the same vendor-lore pattern as BPC-157's spurious 'S2' tag. Monitoring-program status is data-gathering that could inform a future listing decision, so verify against the current annual WADA List before relying on it.]

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Influencer / affiliate incentive — paid weight-loss content and undisclosed-medication controversies (a recurring 2026 social-media pattern; the specific drug in such cases is an undisclosed GLP-1, not confirmed tirzepatide) skew framing toward outsized personal-brand success stories.
• Survivorship / before-after bias — dramatic transformation vlogs are shared far more than plateaus, regains, or discontinuation experiences.
• Telehealth / compounding-vendor marketing pressure mixed into ostensibly organic 'patient experience' content.
• Sentiment mix and the reproductive-symptom share are pooled across the whole GLP-1 class (semaglutide + tirzepatide + liraglutide) — a tirzepatide-isolated sentiment split was not found this pass; the GI/fatigue symptom shares above ARE tirzepatide-isolated (Nature Health 2026).
• AI-generated / SEO 'vendor guide' and affiliate blogs pollute any automated tone read of sourcing/cost content.
• Negativity concentration in insurance-denial and compounding-ban threads may over-represent frustration relative to the large on-label population reporting satisfaction.

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound); once-weekly injection for type 2 diabetes, obesity, and obstructive sleep apnea. Approximately 2,059 articles are indexed (literature last scanned 2026-05-29). US regulatory status: FDA-approved prescription drug (Mounjaro, Zepbound); commercially available; compounding substantially restricted. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet